Search

Author/Creator Sun, Cheng-Ming

2. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Issue 5 (May 2022)

Authors:
Vano, Yann-Alexandre; Elaidi, Réza; Bennamoun, Mostefa; Chevreau, Christine; Borchiellini, Delphine; Pannier, Diane; Maillet, Denis; Gross-Goupil, Marine; Tournigand, Christophe; Laguerre, Brigitte; Barthélémy, Philippe; Coquan, Elodie; Gravis, Gwenaëlle; Houede, Nadine; Cancel, Mathilde; Huillar...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 5(2022)
Page Start:
612
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search